Doctoral Student:
2017 – 2022
Education:
B.S., 2016, Massachusetts Institute of Technology
Research Interest:
Molly is interested in understanding the dysregulation of the PI3K-mTOR signaling network in cancer and uncovering novel therapeutic strategies.
Publications:
Hosios AM, Wilkinson ME, McNamara MC, Kalafut KC, Torrence ME, Asara JM, Manning BD. mTORC1 regulates a lysosome-dependent adaptive shift in intracellular lipid species. Nat Metab. 2022 Dec;4(12):1792-1811. doi: 10.1038/s42255-022-00706-6. Epub 2022 Dec 19. PMID: 36536136; PMCID: PMC9799240.
McNamara MC, Hosios AM, Torrence ME, Zhao T, Fraser C, Wilkinson M, Kwiatkowski DJ, Henske EP, Wu CL, Sarosiek KA, Valvezan AJ, Manning BD. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience. 2022 Oct 28;25(11):105458. doi: 10.1016/j.isci.2022.105458. PMID: 36388985; PMCID: PMC9663903.
Valvezan AJ, McNamara MC, Miller SK, Torrence ME, Asara JM, Henske EP, Manning BD. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. JCI Insight. 2020;5(7):e135071. Published 2020 Apr 9. doi:10.1172/jci.insight.135071. PMID: 32271165
Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ, Asara JM, Henske EP, Manning BD. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. Cancer Cell. 2017; pii: S1535-6108(17)30417-8. PMID: 29056426
Ferretti R, Bhutkar A, McNamara MC, Lees JA. BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes Dev. 2016; 30:18–33. PMID: 26679841